Fifteen years of treatment with intravenous immunoglobulin in central nervous system Langerhans cell histiocytosis

Acta Paediatrica, International Journal of Paediatrics

Volumn 100, Issue 7, 2011, Pages

  Gavhed, Désirée ^a   Laurencikas, Evaldas ^a   Åkefeldt, Selma O ^a   Henter, Jan Inge ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Central nervous system; Intravenous immunoglobulin; Langerhans cell histiocytosis; Therapy

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; METHOTREXATE; PREDNISOLONE; VINBLASTINE;

ADD ON THERAPY; ARTICLE; ATAXIA; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM HISTIOCYTOSIS X; DEGENERATIVE DISEASE; DRUG DOSE REDUCTION; EOSINOPHILIC GRANULOMA; EVOKED AUDITORY RESPONSE; HISTIOCYTOSIS X; HUMAN; INFANT; LUMBAR PUNCTURE; MALE; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SEBORRHEA; SKULL INJURY; TREATMENT DURATION;

ADOLESCENT; CENTRAL NERVOUS SYSTEM DISEASES; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INFANT; MALE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79958065321     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/j.1651-2227.2010.02125.x     Document Type: Article

References (15)

1. Henter JI, Tondini C, Pritchard J,. Histiocytic syndromes. Crit Rev Oncol Hematol 2004; 50: 157-74.
2. Grois N, Fahrner B, Arceci RJ, Henter JI, McClain K, Lassmann H, et al., Central nervous system disease in Langerhans cell histiocytosis. J Pediatr 2010; 156: 873-81.
3. Nanduri VR, Lillywhite L, Chapman C, Parry L, Pritchard J, Vargha-Khadem F,. Cognitive outcome of long-term survivors of multisystem Langerhans cell histiocytosis: a single-institution, cross-sectional study. J Clin Oncol 2003; 21: 2961-7. (Pubitemid 46621848)
4. Bernstrand C, Sandstedt B, Åhström L, Henter JI,. Long-term follow-up of Langerhans cell histiocytosis: 39-year experience at a single center. Acta Paediatr 2005; 94: 1073-84. (Pubitemid 41169657)
5. Fadeel B, Henter JI,. Langerhans cell histiocytosis: neoplasia or unbridled inflammation? Trends Immunol 2003; 24: 409-10.
6. Dalakas MC,. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 1999; 22: 1479.
7. Skansén-Saphir U, Andersson J, Björk L, Ekberg C, Fehniger TE, Henter JI, et al., Down-regulation of lymphokine synthesis by intravenous gammaglobulin is dependent upon accessory cells. Scand J Immunol 1998; 47: 229-35. (Pubitemid 28153400)
8. Jordan S, Toyoda M, Vo A,. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 2009; 88: 1-6.
9. Grois N, Prayer D, Prosch H, Lassmann H,. Neuropathology of CNS disease in Langerhans cell histiocytosis. Brain 2005; 128: 829-38. (Pubitemid 40516920)
10. Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, et al., Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 2008; 111: 715-22.
11. Imashuku S, Okazaki N, Nakayama M, Fujita N, Fukuyama T, Koike K, et al., Treatment of neurodegenerative CNS disease in Langerhans cell histiocytosis with a combination of intravenous immunoglobulin and chemotherapy. Pediatr Blood Cancer 2008; 50: 308-11.
12. Imashuku S,. High dose immunoglobulin (IVIG) may reduce the incidence of Langerhans cell histiocytosis (LCH)-associated central nervous system involvement. CNS Neurol Disord Drug Targets 2009; 8: 380-6.
13. Wnorowski M, Prosch H, Prayer D, Janssen G, Gadner H, Grois N,. Pattern and course of neurodegeneration in Langerhans cell histiocytosis. J Pediatr 2008; 153: 127-32.
14. Gadner H, Grois N, Pötschger U, Minkov M, Arico M, Braier J, et al., Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood 2008; 111: 2556-62.
15. Grois N, Pötschger U, Prosch H, Minkov M, Arico M, Braier J, et al., Risk factors for diabetes insipidus in Langerhans cell histiocytosis. Pediatr Blood Cancer 2006; 46: 228-33. (Pubitemid 43076074)